Kezar Life Sciences shares are trading lower after the company reported a year-over-year decrease in Q2 EPS results. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight, while HC Wainwright lowered its price target from $19 to $18 on the stock.
Benzinga Newsdesk - Aug 11, 2023, 10:30AM